--- description: Nearly half the supply of hydroxychloroquine to the U.S. comes from India, a flow that has now been abruptly stanched it banned exports of all forms of the drug. title: India Cuts off Half the U.S. Supply of a Potential Coronavirus Treatment image: https://static.time.com/v3/assets/bltea6093859af6183b/blt679546b1c86acb3b/698a0c7509208fd8464168e8/coronavirus-treatment.jpg?branch=production&width=2400&quality=75&auto=webp&crop=16:9 ---  * [Business](/section/business/) ## Business Update your preferences in [Account Settings](/account/preferences/) Close * [COVID-19](/tag/covid-19/) ## COVID-19 Update your preferences in [Account Settings](/account/preferences/) Close # India Has Cut Off Half the Supply of a Potential Coronavirus Treatment Touted by Trump by [Lisa Du / Bloomberg](/author/bloomberg/) ## Lisa Du / Bloomberg Update your preferences in [Account Settings](/account/preferences/) Close Apr 6, 2020 10:25 AM CUT  In this photo illustration a pack of Hydroxychloroquine Sulfate medication is held up on March 26, 2020. In this photo illustration a pack of Hydroxychloroquine Sulfate medication is held up on March 26, 2020.John Phillips–Getty Images by [Lisa Du / Bloomberg](/author/bloomberg/) ## Lisa Du / Bloomberg Update your preferences in [Account Settings](/account/preferences/) Close Apr 6, 2020 10:25 AM CUT Nearly half the supply of hydroxychloroquine to the U.S. comes from makers in India, a flow that has now been abruptly stanched after the Asian nation [banned](https://www.bloomberg.com/news/articles/2020-04-05/india-bans-all-exports-of-trump-s-game-changer-virus-drug "undefined") exports of all forms of the malaria drug touted by President Donald Trump as a “game changer” for treating the coronavirus. According to data compiled by Bloomberg Intelligence, 47% of the U.S. supply of the drug last year came from India makers. Only a handful of suppliers in the top 10 are non-Indian, such as Actavis, now a subsidiary of Israeli generics giant Teva Pharmaceutical Industries Ltd. It’s likely that some of their production facilities are nevertheless located in India, the biggest maker of generic drugs in the world. India’s export ban on the drug is aimed at ensuring it has enough supply for domestic use after the American president’s endorsement sparked global [stockpiling](https://www.bloomberg.com/news/articles/2020-03-21/trump-pushes-malaria-drug-for-covid-19-but-evidence-is-lacking "undefined") of the medication. As the coronavirus pandemic widens globally, countries competing for supplies have enacted export bans or restrictions on goods from [rice](https://www.bloomberg.com/news/articles/2020-03-25/vietnam-s-rice-trade-thrown-into-turmoil-on-export-halt-muddle "undefined") in Vietnam to face [masks](https://www.bloomberg.com/news/articles/2020-03-09/germany-faces-backlash-from-neighbors-over-mask-export-ban "undefined") in Germany. While Trump said that the U.S. has secured 29 million choloroquine or hydroxychloroquine pills for its medical stockpile and American drugmakers like Mylan NV have [re-started](http://newsroom.mylan.com/2020-03-19-Mylan-Ramps-Up-U-S-Manufacturing-of-Hydroxychloroquine-Sulfate-Tablets-to-Meet-Potential-COVID-19-Patient-Needs "undefined") production of the tablets to meet U.S. needs, the India ban will likely push prices of the medication up in the short-term, while limiting available supply in the long-term. The active chemical compound needed to make the drug is also mainly supplied through Indian channels and is now banned for export too, potentially complicating efforts like Mylan’s. There’s no conclusive scientific evidence that hydroxychloroquine can treat the infection from the novel coronavirus, and it hasn’t been approved by the Food and Drug Administration in the U.S. for Covid-19. India’s April 4 move was an expansion of an announcement last month which banned overseas shipments of the drug except for those to meet prior commitments and for humanitarian grounds. There are now no exceptions to the export ban. The top U.S. supplier of hydroxychloroquine, Zydus Pharmaceuticals Inc., is a subsidiary of Ahmedabad, India-based Cadila Healthcare Ltd. It sold over 167 million units of the anti-malarial in 2019, according to Bloomberg data, and has supplied 28 million integrated units to retail and institutional channels in the U.S. so far this year. Prior to the ban, Cadila said it was planning to ramp up production of hydroxychloroquine tenfold to meet surging global demand. –With assistance from Ari Altstedter. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/5816105/coronavirus-treatment-cut-off-india/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/5816105/coronavirus-treatment-cut-off-india/"},"headline":"India Has Cut Off Half the Supply of a Potential Coronavirus Treatment Touted by Trump","datePublished":"2020-04-06T10:25:22.000Z","dateModified":"2026-02-24T08:34:38.454Z","description":"Nearly half the supply of hydroxychloroquine to the U.S. comes from India, a flow that has now been abruptly stanched it banned exports of all forms of the drug.","url":"https://time.com/5816105/coronavirus-treatment-cut-off-india/","keywords":["COVID-19","wire","overnight"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt679546b1c86acb3b/698a0c7509208fd8464168e8/coronavirus-treatment.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Lisa Du / Bloomberg"}],"articleSection":"Business","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt679546b1c86acb3b/698a0c7509208fd8464168e8/coronavirus-treatment.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Hydroxychloroquine Sulfate Medication Illustration","caption":"Hydroxychloroquine Sulfate Medication Illustration","creditText":"John Phillips–Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/business/","name":"Business"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/5816105/coronavirus-treatment-cut-off-india/","name":"India Has Cut Off Half the Supply of a Potential Coronavirus Treatment Touted by Trump"}}]}] ```